Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies.

While post-hoc analyses of AUC 0–6 for SKAMP-Combined scores showed trends, nearing statistical significance, favouring Focalin XR ® (20 and 30 mg) over higher daily doses of Concerta ® (36 and 54 mg), differences between the two MPH formulations from 6 to 12 hours post-dose (AUC 6–12 ) failed to reach significance (20 versus 36 mg, p = 0.244; 30 versus 54 mg, p = 0.594) [ 33 ].

also in 4,113 other papers